Skip to content

Advertisement

  • Short report
  • Open Access

Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation

  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 3, 4,
  • 3 and
  • 1Email author
Journal of Neuroinflammation201815:60

https://doi.org/10.1186/s12974-018-1098-4

  • Received: 18 December 2017
  • Accepted: 19 February 2018
  • Published:

Abstract

Background

Several psychiatric conditions are affected by neuroinflammation and neuroimmune activation. The transcription factor nuclear factor kappa light-chain-enhancer of activated B cells (NFkB) plays a major role in inflammation and innate immunity. The neurokinin-1 receptor (NK1R) is the primary endogenous target of the neuroactive peptide substance P, and some data suggests that NK1R stimulation may influence NFkB activity. Both NK1R and NFkB have been shown to play a functional role in complex behaviors including stress responsivity, depression, and addiction. In this study, we test whether NFkB activity in the brain (stimulated by lipopolysaccharide administration) is dependent upon the NK1R.

Methods

Adult male Wistar rats were treated systemically with the NK1R antagonist L822429 followed by administration of systemic lipopolysaccharide (LPS, a strong activator of NFkB). Hippocampal extracts were used to assess expression of proinflammatory cytokines and NFkB-DNA-binding potential. For behavioral studies, rats were trained to consume 1% (w/v) sucrose solution in a continuous access two-bottle choice model. After establishment of baseline, animals were treated with L822429 and LPS and sucrose preference was measured 12 h post-treatment.

Results

Systemic LPS treatment causes a significant increase in proinflammatory cytokine expression and NFkB-DNA-binding activity within the hippocampus. These increases are attenuated by systemic pretreatment with the NK1R antagonist L822429. Systemic LPS treatment also led to the development of anhedonic-like behavior, evidenced by decreased sucrose intake in the sucrose preference test. This behavior was significantly attenuated by systemic pretreatment with the NK1R antagonist L822429.

Conclusions

Systemic LPS treatment induced significant increases in NFkB activity, evidenced by increased NFkB-DNA binding and by increased proinflammatory cytokine expression in the hippocampus. LPS also induced anhedonic-like behavior. Both the molecular and behavioral effects of LPS treatment were significantly attenuated by systemic NK1R antagonism, suggesting that NK1R stimulation lies upstream of NFkB activation following systemic LPS administration and is at least in part responsible for NFkB activation.

Keywords

  • Neurokinin-1 receptor
  • Nuclear factor kappa B
  • Lipopolysaccharide
  • Inflammation
  • Cytokines
  • Anhedonia
  • Depression
  • Neuroimmune system

Background

Discovered by Sen and Baltimore in 1986, nuclear factor kappa light-chain-enhancer of activated B cells (NFkB) is a widely expressed transcription factor known for its involvement in inflammation and the innate immune system [13]. NFkB is activated after exposure to a variety of stimuli, such as oxidative stressors or pathogens, and induces the expression of genes involved in the innate immune response [4]. For example, systemic treatment with lipopolysaccharide (LPS), a bacterial endotoxin, leads to significant increases in NFkB activity and proinflammatory cytokine production [5]. NFkB activation and subsequent cytokine production have also been shown to influence depressive-like behaviors, specifically social avoidance and anhedonia [611]. Human studies have also demonstrated that NFkB activation by low-dose LPS injection induces anhedonia, as evidenced by decreased striatal activity during a reward-related task, and LPS-exposed subjects also reported depressed mood [12]. Additional studies have also found that stress-induced anhedonia and decreased hippocampal neurogenesis are dependent on the proinflammatory cytokine interleukin-1β (IL-1β) and NFkB activation [13].

The neurokinin-1 receptor (NK1R) is the primary endogenous target of the neuropeptide substance P (SP). SP and the NK1R are widely expressed throughout the central nervous system (CNS) and, like NFkB, are involved in stress, anxiety, and depression [1420]. The NK1R has also been found to play a prominent role in inflammatory responses within the CNS and in the periphery via a process known as neurogenic inflammation [21, 22]. NK1Rs are expressed by glial cells, and their stimulation by SP can enhance the expression and release of inflammatory cytokines [2325]. NK1R inhibition, either by genetic deletion or pharmacological antagonism, also attenuates CNS inflammation in response to bacterial infection [2628].

The NK1R and NFkB have been found to interact directly. For example, NK1R stimulation leads to increased NFkB activation [24, 25, 29]. Treatment with SP causes increased NFkB activation and proinflammatory cytokine production, which is attenuated by selective NK1R antagonism [30, 31]. This relationship may be bidirectional, as it is known that the TACR1 gene (gene for NK1R) contains NFkB responsive elements in its promoter [32]. In regard to LPS treatment specifically, NK1R antagonist treatment prevents cytokine release and the detrimental effects of LPS exposure in the lung and liver [31, 33]. Additionally, the central SP/NK1R system mediates the fever response to peripheral LPS administration [34, 35]. However, the role of the NK1R specifically in LPS-induced cytokine expression and NFkB activation within the CNS, and the resulting behavioral consequences, has not been assessed in an in vivo model.

The current study aims to characterize the cellular relationship between the NK1R and NFkB systems in the brain, as well as resulting effects on behavior, specifically, motivated behavior that drives sucrose consumption. We hypothesized that systemic antagonism of the NK1R prior to LPS administration would prevent the LPS-induced increase in NFkB activity, proinflammatory cytokine expression, and anhedonic behavior.

Methods

Animals

All experiments were conducted using adult male Wistar rats (Charles River Laboratories, 175–200 g at time of arrival). All rats were provided food and water ad libitum and were housed on a 12:12 light/dark cycle. After arrival, animals were allowed 1 week to habituate to the facility and an additional week of handling prior to any experimentation. Rats used for electrophoretic mobility shift assay (EMSA) and quantitative polymerase chain reaction (qPCR) experiments were group housed, and rats used for the sucrose preference experiment were singly housed. All procedures were approved by the Institutional Animal Care and Use Committee and were in accordance with NIH guidelines.

L822429 and lipopolysaccharide treatment

The NK1R antagonist L822429 was dissolved in 2-hydroxypropyl-β-cyclodextrin (45% w/v) and injected i.p. at a dose of 30 mg/kg in a volume of 2 ml/kg. L822429 treatment was administered 1 h prior to LPS treatment. LPS (strain 0111:B4, Sigma) was dissolved in sterile 0.9% saline and injected i.p. at a dose of 200 μg/kg in a volume of 1 ml/kg. In EMSA and qPCR experiments, rats were sacrificed by live decapitation 2 h after injection. Brains were extracted, hippocampal tissue was dissected, and samples were snap frozen in isopentane. Samples were stored at − 80 °C until tissue processing.

Electrophoretic mobility shift assay

To investigate the role of the NK1R in LPS-induced activation of NFkB-DNA-binding potential, rats (n = 6/group) were treated systemically with vehicle or L822429 followed by injection of saline or LPS. Nuclear protein extracts were prepared using Active Motif Nuclear Extract Kit (Active Motif), and protein concentration in each sample was determined using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific). For EMSA, nuclear protein samples (15 μg) were incubated with Odyssey® EMSA Buffer Kit (LI-COR) and NFkB IRDye® 700 infrared dye-labeled oligonucleotide. Loading dye was added to each sample, and the gel (6% DNA retardation gel, Invitrogen, Life Technologies) was run at 200 V at 4 °C. Gels were imaged, and band intensity was quantified using Li-Cor Odyssey CLx Infrared Imaging System.

Quantitative polymerase chain reaction

The expression of proinflammatory cytokines IL1β, IL6, and TNFα is known to be strongly activated by NFkB. To evaluate the role of the NK1R in LPS-induced increases in proinflammatory cytokine expression, rats (n = 5–6/group) were treated systemically with vehicle or L822429 followed by injection of saline or LPS. Hippocampal samples were homogenized, and RNA was extracted using PureLink™ RNA Mini Kit (Ambion, Life Technologies) according to the manufacturer’s instructions. We chose to analyze cytokine mRNA levels within the hippocampus based on previous work demonstrating a significant effect of LPS treatment on proinflammatory cytokine expression in this region [36, 37]. Samples were then reversed transcribed using SuperScript® III Kit (Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s instructions. qPCR was performed on each sample in triplicate using the following Taqman primers: TNF-α (Rn0152859_g1), IL-6 (Rn0140330_m1), IL-1β (Rn0058432_m1), and GAPDH for internal control (Rn01775763_g1; Life Technologies). qPCR analysis was performed on a Life Technologies QuantStudio6 machine.

Sucrose preference test

To assess the effect of NK1R antagonism on LPS-induced anhedonic-like behavior, a sucrose preference test was conducted [3840]. Rats (n = 6/group) were provided with one bottle containing 1% (w/v) sucrose solution and one bottle containing water for 2 days to establish a baseline sucrose preference. Bottle position was switched every 24 h to prevent development of a side preference. Sucrose solution was then removed so that only water was available, and rats were treated with L822429 or vehicle, followed by saline or LPS. The 1% sucrose solution was reintroduced 12 h after LPS treatment, and water and sucrose intake was measured 12 h later. Baseline and post-treatment sucrose preference was expressed as proportion of fluid intake that was accounted for by consumption from the sucrose bottle. For example, a value of 0.8 would indicate that 80% of the total fluid consumption was from the bottle containing the sucrose solution.

Results

NK1R antagonism attenuates LPS-induced increase in NFkB-DNA-binding potential in the hippocampus

One-way ANOVA indicated that optical density of shift bands in the EMSA assay were significantly different between treatment groups (Fig. 1a, F2,15 = 6.158, p < 0.05). Representative image shown in Fig. 1b. Post hoc analysis using Newman-Keuls tests revealed that vehicle-LPS-treated subjects had significantly higher intensity when compared to both vehicle-saline-treated subjects and L822429-LPS treated subjects (p < 0.05 for both comparisons). Intensity in the L822429-LPS-treated group was not significantly different from the vehicle-saline-treated group. This suggests that LPS induced an increase in NFkB translocation to the nucleus and NFkB-DNA-binding potential that was attenuated by pretreatment with the NK1R antagonist.
Fig. 1
Fig. 1

Effect of neurokinin-1 (NK1R) antagonism on LPS-induced increase in NFkB-DNA-binding activity in the hippocampus. Rats were treated with L822429 (30 mg/kg) 1 h prior to LPS (200 μg/kg) and sacrificed 2 h after LPS injection. a Electrophoretic mobility shift assay (EMSA) quantification: data expressed as percent of vehicle-saline control. b Representative image of EMSA results. n = 6/group. *p < 0.05, compared to the vehicle-saline, #p < 0.05 compared to the vehicle-LPS

NK1R antagonism attenuates LPS-induced increase in proinflammatory cytokine expression in the hippocampus

One-way ANOVA revealed that IL-1β, TNF-α, and IL-6 mRNA levels were significantly different between treatment groups (Fig. 2a: F2,13 = 31.89, p < 0.0001; Fig. 2b: F2,13 = 25.29, p < 0.0001; Fig. 2c: F2,13 = 7.048, p < 0.01, respectively). Post hoc analysis using Newman-Keuls tests revealed that the vehicle-LPS-treated group had significantly higher expression of IL-1β, TNF-α, and IL-6 when compared to the vehicle-saline-treated group (p < 0.001, p < 0.001, and p < 0.05, respectively) and when compared to the L822429-LPS-treated group (p < 0.001, p < 0.001, and p < 0.01, respectively). IL-1β, TNF-α, and IL-6 levels were not significantly different between L822429-LPS-treated and vehicle-saline-treated groups. These results indicate that LPS induces increased expression of proinflammatory cytokines in the hippocampus and this is attenuated by NK1R antagonism.
Fig. 2
Fig. 2

Effect of neurokinin-1 receptor (NK1R) antagonism on LPS-induced increase in proinflammatory cytokine expression in the hippocampus. Rats were treated with L822429 (30 mg/kg) 1 h prior to LPS (200 μg/kg) and sacrificed 2 h after LPS injection. mRNA transcript levels were measured using qPCR. NK1R antagonism attenuates LPS-induced increase in expression of 1L1-β (a), TNF-α (b), and IL-6 (c). n = 5–6/group. *p < 0.05, ***p < 0.001, compared to the vehicle-saline group. ##p < 0.01, ###p < 0.001, compared to the vehicle-LPS group

NK1R antagonism attenuates LPS-induced anhedonia

Two-way ANOVA revealed a significant effect of test phase (baseline versus post-treatment; F1,15 = 11.03, p < 0.01) and a significant interaction between the factors of test phase and treatment (F2,15 = 4.512, p < 0.05). Post hoc analysis using Newman-Keuls tests revealed that during the baseline phase, the average sucrose preference did not differ between groups. However, the vehicle-LPS-treated group had significantly decreased sucrose preference post-treatment when compared to both the vehicle-saline-treated group and the L822429-LPS-treated group (Fig. 3, p < 0.01 for both comparisons). Sucrose preference post-treatment in the L822429-LPS-treated group and the vehicle-saline-treated group were not significantly different. These data suggest that NK1R activation is, at least in part, required for LPS-induced suppression of sucrose preference.
Fig. 3
Fig. 3

Effect of neurokinin-1 (NK1R) antagonism on LPS-induced anhedonia. Rats were treated with L822429 (30 mg/kg) 1 h prior to LPS (200 μg/kg) and sucrose consumption began 12 h after LPS injection. Systemic treatment with 200 μg/kg LPS decreases voluntary sucrose consumption in the two-bottle choice test. NK1R antagonism with systemic administration of 30 mg/kg L822429 attenuates LPS-induced decrease in sucrose preference. Data shown was collected 12 h post-LPS treatment. n = 6/group. **p < 0.01, compared to the vehicle-saline group, ##p < 0.01 compared to the vehicle-LPS group

Discussion

In this study, we demonstrate that the cellular and behavioral effects of LPS administration are in part dependent upon NK1R signaling. First, we show that NFkB-DNA-binding potential and subsequent expression of proinflammatory cytokines by systemic LPS injection is attenuated by systemic injection of the NK1R antagonist L822429. We show these effects in ex vivo brain tissue homogenates from the hippocampus. In previous studies, the role of NK1R in LPS-induced cellular effects has been demonstrated in vitro or in non-neural tissue; here, we extend those findings to show that this mechanism functions in the nervous system in vivo. Furthermore, many in vivo studies examining the impact of LPS on NFkB activation use the endpoint measure of cytokine expression. Here, we use this measure as well but also demonstrate that NFkB binding potential is increased by systemic LPS treatment. This is important because NFkB is unlikely to be the only transcription factor that influences the expression of proinflammatory genes. Additionally, we show that the anhedonia-inducing effects of LPS administration are also influenced by the NK1R. Thus, both the cellular and behavioral effects of LPS injection depend, at least in part, upon the action of the NK1R.

In this study, we assessed the effect of systemic administration of LPS on NFkB/cytokine activity in the hippocampus. However, it is unlikely that LPS injected through the intraperitoneal route reaches the brain. Thus, there is likely to be an intermediate signaling process that induces the CNS effect that we observe. Alternatively, NK1R actions in the periphery could influence the amount of peripheral cytokine release that is induced following LPS injection. Future experiments will examine these specific routes by which the NK1R may influence LPS effects.

Here, we show that LPS-induced anhedonia is influenced by NK1R activation. In addition to this anhedonia effect, LPS exposure has been shown to influence other behaviors of interest including sensitivity to painful stimuli [41], alcohol intake [42], and anxiety [43, 44]. Future studies will examine the role of the NK1R in additional LPS-induced behaviors. This is of particular interest because there is a considerable overlap between the types of behaviors that are influenced by NK1R signaling and those that are induced by LPS.

Conclusions

Taken together, the results presented here suggest that the NK1R contributes to multiple aspects of LPS challenge. The role of the NK1R may also extend to neuroinflammatory responses in general, and this receptor may thus influence psychiatric conditions that are mediated by chronic inflammation including depression, chronic pain, alcohol dependence, and others. FDA-approved NK1R antagonists are currently on the market; aprepitant has been used for several years to treat chemotherapy-induced nausea. Therefore, the efficacy of this drug could be tested in clinical trials for psychiatric conditions mediated by inflammation. While past clinical trials using NK1R antagonists have produced mixed results, negative findings have possibly been influenced by complex factors including drug dosing and pharmacogenetic interactions (see [45, 46] for discussion of this topic).

Abbreviations

EMSA: 

Electrophoretic mobility shift assay

IL-1β: 

Interleukin-1β

LPS: 

Lipopolysaccharide

NFkB: 

Nuclear factor kappa light-chain-enhancer of activated B cells

NK1R: 

Neurokinin-1 receptor

qPCR: 

Quantitative polymerase chain reaction

SP: 

Substance P

TNF-α: 

Tumor necrosis factor-α

Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by NIH K99/R00 Pathway to Independence Award AA021805 (J.R.S.). A portion of this work was supported by the intramural research programs of the National Institute on Drug Abuse and the National Institute on Alcoholism and Alcohol Abuse (K.C.R).

Availability of data and materials

The datasets generated during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HDF and JRS wrote the manuscript. HDF, BMS, ASN, JMC, SEN, and JRS contributed to data collection and analysis. KC and KCR synthesized L822429. All authors read and approved the final manuscript.

Ethics approval

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, 501 D.W. Brooks Drive, Athens, GA 30602, USA
(2)
Department of Kinesiology, University of Georgia, 115 Ramsey Center, 330 River Road, Athens, GA 30602, USA
(3)
NIDA and NIAAA IRP, 9800 Medical Center Drive, Rm 228A MSC-3373, Bethesda, MD 20892, USA
(4)
Present Address: Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

References

  1. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999;18(49):6867–74.View ArticlePubMedGoogle Scholar
  2. Manning AM, et al. NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm. 1995;45(4):283–96.PubMedGoogle Scholar
  3. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(5):705–16.View ArticlePubMedGoogle Scholar
  4. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Odkhuu E, et al. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B. Immunobiology. 2015;220(1):136–41.View ArticlePubMedGoogle Scholar
  6. Hodes GE, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci U S A. 2014;111(45):16136–41.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Liu YM, et al. Ferulic acid inhibits neuro-inflammation in mice exposed to chronic unpredictable mild stress. Int Immunopharmacol. 2017;45:128–34.View ArticlePubMedGoogle Scholar
  8. Bali A, Jaggi AS. Investigations on GSK-3beta/NF-kB signaling in stress and stress adaptive behavior in electric foot shock subjected mice. Behav Brain Res. 2016;302:1–10.View ArticlePubMedGoogle Scholar
  9. Koo JW, et al. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A. 2010;107(6):2669–74.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Christoffel DJ, et al. IkappaB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J Neurosci. 2011;31(1):314–21.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Christoffel DJ, et al. Effects of inhibitor of kappaB kinase activity in the nucleus accumbens on emotional behavior. Neuropsychopharmacology. 2012;37(12):2615–23.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Eisenberger NI, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68(8):748–54.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105(2):751–6.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Santarelli L, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A. 2001;98(4):1912–7.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Ebner K, et al. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci. 2008;1144:61–73.View ArticlePubMedGoogle Scholar
  16. Hutson PH, et al. Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK1 receptor antagonist. Eur J Pharmacol. 2004;484(1):57–64.View ArticlePubMedGoogle Scholar
  17. Singewald N, et al. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem. 2008;106(6):2476–88.View ArticlePubMedGoogle Scholar
  18. Renoldi G, Invernizzi RW. Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J Neurosci Res. 2006;84(5):961–8.View ArticlePubMedGoogle Scholar
  19. Frick A, et al. Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171. Transl Psychiatry. 2015;5:e597.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Ebner K, et al. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci U S A. 2004;101(12):4280–5.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Johnson MB, Young AD, Marriott I. The therapeutic potential of targeting substance P/NK-1R interactions in inflammatory CNS disorders. Front Cell Neurosci. 2016;10:296.View ArticlePubMedGoogle Scholar
  22. Martinez AN, Philipp MT. Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system. J Neurol Neuromedicine. 2016;1(2):29–36.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241(4870):1218–21.View ArticlePubMedGoogle Scholar
  24. Burmeister AR, et al. Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P. J Neuroinflammation. 2017;14(1):245.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Rasley A, et al. Expression of functional NK-1 receptors in murine microglia. Glia. 2002;37(3):258–67.View ArticlePubMedGoogle Scholar
  26. Martinez AN, et al. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation. 2017;14(1):37.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Chauhan VS, et al. Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi. J Immunol. 2008;180(12):8241–9.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Chauhan VS, et al. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol. 2011;186(12):7255–63.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Sun J, et al. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol. 2008;294(6):C1586–96.View ArticlePubMedGoogle Scholar
  30. Williams R, Zou X, Hoyle GW. Tachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-kappaB via a G(q)-dependent pathway. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L430–7.View ArticlePubMedGoogle Scholar
  31. Bang R, et al. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther. 2003;305(1):31–9.View ArticlePubMedGoogle Scholar
  32. Simeonidis S, et al. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci U S A. 2003;100(5):2957–62.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Veron M, et al. Interactions of tachykinin receptor antagonists with lipopolysaccharide-induced airway inflammation in mice. Clin Exp Pharmacol Physiol. 2004;31(9):634–40.View ArticlePubMedGoogle Scholar
  34. Szelenyi Z, Szekely M, Balasko M. Role of substance P (SP) in the mediation of endotoxin (LPS) fever in rats. Ann N Y Acad Sci. 1997;813:316–23.View ArticlePubMedGoogle Scholar
  35. Reis RC, et al. Central substance P NK(1) receptors are involved in fever induced by LPS but not by IL-1beta and CCL3/MIP-1alpha in rats. Brain Res. 2011;1384:161–9.View ArticlePubMedGoogle Scholar
  36. Abramova AY, et al. Cytokine levels in rat blood and brain structures after administration of lipopolysaccharide. Bull Exp Biol Med. 2013;155(4):417–20.View ArticlePubMedGoogle Scholar
  37. Turrin NP, et al. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull. 2001;54(4):443–53.View ArticlePubMedGoogle Scholar
  38. Strekalova T, Steinbusch HW. Measuring behavior in mice with chronic stress depression paradigm. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(2):348–61.View ArticleGoogle Scholar
  39. Valvassori SS, et al. Contributions of animal models to the study of mood disorders. Rev Bras Psiquiatr. 2013;35(Suppl 2):S121–31.View ArticlePubMedGoogle Scholar
  40. Willner P, et al. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology. 1987;93(3):358–64.View ArticlePubMedGoogle Scholar
  41. Calil IL, et al. Lipopolysaccharide induces inflammatory hyperalgesia triggering a TLR4/MyD88-dependent cytokine cascade in the mice paw. PLoS One. 2014;9(3):e90013.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Blednov YA, et al. Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice. Brain Behav Immun. 2011;25(Suppl 1):S92–S105.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Jangra A, et al. Protective effect of mangiferin against lipopolysaccharide-induced depressive and anxiety-like behaviour in mice. Eur J Pharmacol. 2014;740:337–45.View ArticlePubMedGoogle Scholar
  44. Sulakhiya K, et al. Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin. Neurosci Lett. 2016;611:106–11.View ArticlePubMedGoogle Scholar
  45. Schank JR. The neurokinin-1 receptor in addictive processes. J Pharmacol Exp Ther. 2014;351(1):2–8.View ArticlePubMedGoogle Scholar
  46. Schank JR, Heilig M. Substance P and the Neurokinin-1 receptor: the new CRF. Int Rev Neurobiol. 2017;136:151–75.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement